Background: Evaluating the tumor proliferative index helps predict clinical behavior and provides prognostic insights for cutaneous basal cell carcinoma (cBCC) and squamous cell carcinoma (cSCC). Objective: This study...Background: Evaluating the tumor proliferative index helps predict clinical behavior and provides prognostic insights for cutaneous basal cell carcinoma (cBCC) and squamous cell carcinoma (cSCC). Objective: This study aimed to identify differences in the proliferative indices among variants of cBCC and cSCC diagnosed at a tertiary healthcare center. Method: Skin biopsies histologically diagnosed as cBCC and cSCC between 2012 and 2018 at the Federal Medical Centre (FMC) Umuahia, Abia State, Nigeria, were analyzed. Archival formalin-fixed, paraffin-embedded (FFPE) tissue blocks were retrieved along with clinical data, and were prepared on charged microscope slides and the immunohistochemical staining was carried out. The primary antibody used in this study was clone BioCare CRM325C (RM) and adenotonsillar tissue blocks/slides served as positive controls. Ki-67 immunohistochemistry was performed on fresh 4µm sections of the tumor specimens. Results: The application of Ki-67 immunoperoxidase on both BCC and SCC cohort, yielded an intense observable brownish nuclear stain in areas of dense proliferating tumour cells on both cutaneous tumours. The average Ki-67 index for all cSCC cases was 24.7%, with a range of 2.3% - 80%, while the mean for cBCC was 15.8%, ranging from 1.2% - 45.6%. Variants with high proliferative indices were observed in 11.9% of cBCC cases and 29.1% of cSCC cases. Among the low proliferative index category, cSCC accounted for 5.4%, while cBCC represented 14.3%. For mild proliferative indices, cSCC cases made up 7.3% and cBCC, 11.9%. The majority of cases showed moderate proliferative indices, with 61.9% for cBCC and 58.2% for cSCC. Overall, there was a significant difference in proliferative indices between cSCC, cBCC, and their variants. Conclusion: The study found a significantly higher rate of cell proliferation, measured by Ki-67 immunostaining, in cSCC and its variants compared to cBCC. However, certain variants of cBCC also exhibited high Ki-67 expression, indicating they can be as aggressive as some cSCC variants.展开更多
AIM: To investigate the expression and prognostic value of carbonic anhydrase Ⅱ (CA Ⅱ) and Ki-67 in gastrointestinal stromal tumors (GISTs). METHODS: One hundred and thirteen GIST patients admitted to Chinese People...AIM: To investigate the expression and prognostic value of carbonic anhydrase Ⅱ (CA Ⅱ) and Ki-67 in gastrointestinal stromal tumors (GISTs). METHODS: One hundred and thirteen GIST patients admitted to Chinese People's Liberation Army General Hospital from January 2004 to December 2010 were retrospectively followed up, and immunohistochemistry was used to detect CA Ⅱ, Ki-67 and CD117 expression in tumor samples. The survival rates of the patients were analyzed using the Kaplan-Meier method. Log-rank test, χ 2 test and Cox proportional hazards model were used to determine the relationships between CA Ⅱ, Ki-67 and CD117 expression and prognostic value in GISTs. RESULTS: The survival rates at 1, 3 and 5 years were 90.0%, 82.0% and 72.0% in all patients. However, in patients with positive CA Ⅱ or Ki-67, the survival rates were 92.0%, 83.0% and 77.0% or 83.0%, 66.6% and 53.0%, respectively. Compared with the negative groups, the survival rates in the positive groups were significantly lower (CA Ⅱ log-rankP = 0.000; Ki-67 logrank P = 0.004). Multivariate Cox analysis revealed that CA Ⅱ, CD117 and Ki-67 were considerable immune factors in prognosis of GIST patients (CA Ⅱ P = 0.043; CD117 P = 0.042; Ki-67 P = 0.007). Besides, tumor diameter, mitotic rate, tumor site, depth of invasion, complete resection, intraoperative rupture, and adjuvant therapy were important prognosis predictive factors. Our study indicated that CA Ⅱ had strong expression in GISTs and the prognosis of GISTs with high CA Ⅱ expression was better than that of GISTs with low or no expression, suggesting that CA Ⅱ is both a diagnostic and prognostic biomarker for GIST. CONCLUSION: CA Ⅱ and Ki-67 are significant prognostic factors for GISTs. CA Ⅱ associated with neovascular endothelia could serve as a potential target for cancer therapy.展开更多
目的探讨多模态磁共振成像技术及其定量和定性参数预测胶质瘤Ki-67表达水平的价值。材料与方法选取330例胶质瘤患者,其中异柠檬酸脱氢酶(isocitrate dehydrogenase,IDH)野生型201例,IDH突变型129例。获得常规MRI特征、表观扩散系数(appa...目的探讨多模态磁共振成像技术及其定量和定性参数预测胶质瘤Ki-67表达水平的价值。材料与方法选取330例胶质瘤患者,其中异柠檬酸脱氢酶(isocitrate dehydrogenase,IDH)野生型201例,IDH突变型129例。获得常规MRI特征、表观扩散系数(apparentdiffusion coefficient,ADC)、动态对比增强(dynamic contrast-enhanced,DCE)MRI定性及定量参数时间-强度曲线(time-intensity curve,TIC)、转运常数(volume transfer constant,K^(trans))、渗出速率常数(the rate constant,K_(ep))、血管外细胞外容积分数(fractional volume of the extravascular-extracellular,V_(e))、血浆分数(plasma fraction,V_(p))及磁共振波谱(magnetic resonance spectroscopy,MRS)代谢产物比值,对胶质瘤患者进行logistic回归,以确定与Ki-67表达水平相关因素。用受试者工作特征曲线下面积(area under the curve,AUC)评价预测模型的性能。结果在胶质瘤患者分析中,K^(trans)(OR=1.012,P<0.001)、ADC(OR=0.998,P<0.05)、强化程度(OR=3.317,P<0.05)是Ki-67表达水平的独立预测因素,AUC为0.893。结论K^(trans)、ADC和强化程度可能是预测胶质瘤Ki-67表达水平的有效参数。展开更多
文摘Background: Evaluating the tumor proliferative index helps predict clinical behavior and provides prognostic insights for cutaneous basal cell carcinoma (cBCC) and squamous cell carcinoma (cSCC). Objective: This study aimed to identify differences in the proliferative indices among variants of cBCC and cSCC diagnosed at a tertiary healthcare center. Method: Skin biopsies histologically diagnosed as cBCC and cSCC between 2012 and 2018 at the Federal Medical Centre (FMC) Umuahia, Abia State, Nigeria, were analyzed. Archival formalin-fixed, paraffin-embedded (FFPE) tissue blocks were retrieved along with clinical data, and were prepared on charged microscope slides and the immunohistochemical staining was carried out. The primary antibody used in this study was clone BioCare CRM325C (RM) and adenotonsillar tissue blocks/slides served as positive controls. Ki-67 immunohistochemistry was performed on fresh 4µm sections of the tumor specimens. Results: The application of Ki-67 immunoperoxidase on both BCC and SCC cohort, yielded an intense observable brownish nuclear stain in areas of dense proliferating tumour cells on both cutaneous tumours. The average Ki-67 index for all cSCC cases was 24.7%, with a range of 2.3% - 80%, while the mean for cBCC was 15.8%, ranging from 1.2% - 45.6%. Variants with high proliferative indices were observed in 11.9% of cBCC cases and 29.1% of cSCC cases. Among the low proliferative index category, cSCC accounted for 5.4%, while cBCC represented 14.3%. For mild proliferative indices, cSCC cases made up 7.3% and cBCC, 11.9%. The majority of cases showed moderate proliferative indices, with 61.9% for cBCC and 58.2% for cSCC. Overall, there was a significant difference in proliferative indices between cSCC, cBCC, and their variants. Conclusion: The study found a significantly higher rate of cell proliferation, measured by Ki-67 immunostaining, in cSCC and its variants compared to cBCC. However, certain variants of cBCC also exhibited high Ki-67 expression, indicating they can be as aggressive as some cSCC variants.
文摘AIM: To investigate the expression and prognostic value of carbonic anhydrase Ⅱ (CA Ⅱ) and Ki-67 in gastrointestinal stromal tumors (GISTs). METHODS: One hundred and thirteen GIST patients admitted to Chinese People's Liberation Army General Hospital from January 2004 to December 2010 were retrospectively followed up, and immunohistochemistry was used to detect CA Ⅱ, Ki-67 and CD117 expression in tumor samples. The survival rates of the patients were analyzed using the Kaplan-Meier method. Log-rank test, χ 2 test and Cox proportional hazards model were used to determine the relationships between CA Ⅱ, Ki-67 and CD117 expression and prognostic value in GISTs. RESULTS: The survival rates at 1, 3 and 5 years were 90.0%, 82.0% and 72.0% in all patients. However, in patients with positive CA Ⅱ or Ki-67, the survival rates were 92.0%, 83.0% and 77.0% or 83.0%, 66.6% and 53.0%, respectively. Compared with the negative groups, the survival rates in the positive groups were significantly lower (CA Ⅱ log-rankP = 0.000; Ki-67 logrank P = 0.004). Multivariate Cox analysis revealed that CA Ⅱ, CD117 and Ki-67 were considerable immune factors in prognosis of GIST patients (CA Ⅱ P = 0.043; CD117 P = 0.042; Ki-67 P = 0.007). Besides, tumor diameter, mitotic rate, tumor site, depth of invasion, complete resection, intraoperative rupture, and adjuvant therapy were important prognosis predictive factors. Our study indicated that CA Ⅱ had strong expression in GISTs and the prognosis of GISTs with high CA Ⅱ expression was better than that of GISTs with low or no expression, suggesting that CA Ⅱ is both a diagnostic and prognostic biomarker for GIST. CONCLUSION: CA Ⅱ and Ki-67 are significant prognostic factors for GISTs. CA Ⅱ associated with neovascular endothelia could serve as a potential target for cancer therapy.
文摘目的探讨表观扩散系数(apparent diffusion coefficient,ADC)鉴别诊断肺癌脑转移瘤组织学分型的价值及其与Ki-67增殖指数之间的关系。材料与方法回顾性分析经手术病理证实的20例小细胞肺癌脑转移瘤和41例非小细胞肺癌脑转移瘤患者的资料,并测定其Ki-67增殖指数。在ADC图上测量肿瘤实性部分的最小ADC值(the minimum ADC,ADCmin)、平均ADC值(the mean ADC,ADCmean)及对侧正常脑白质ADC值,并计算相对ADCmin(relative ADCmin,rADCmin)及相对ADCmean(relative ADCmean,rADCmean)。对比分析二者ADC值的差异,绘制受试者工作特征(receiver operating characteristic,ROC)曲线评价ADC值的鉴别诊断价值,并计算ADC值与Ki-67增殖指数之间的相关性。结果小细胞肺癌脑转移瘤组的ADCmin、ADCmean、rADCmin及rADCmean值均小于非小细胞肺癌脑转移瘤组,组间差异均具有统计学意义(P<0.05)。各ADC值均能对小细胞肺癌脑转移瘤及非小细胞肺癌脑转移瘤进行有效鉴别,其中rADCmean值的鉴别诊断效能最好,曲线下面积(area under the curve,AUC)为0.950[95%置信区间(confidence interval,CI):0.907~0.994],最佳截断值为0.955,相应的敏感度和特异度分别为96.23%、83.87%,准确度为91.67%。小细胞肺癌脑转移瘤组的Ki-67增殖指数大于非小细胞肺癌脑转移瘤组,组间差异具有统计学意义(P<0.05)。61例肺癌脑转移瘤患者的ADCmin、ADCmean、rADCmin及rADCmean值均与Ki-67增殖指数呈不同程度的负相关(r=-0.506、r=-0.480、r=-0.569、r=-0.541)。结论ADC值可以对肺癌脑转移瘤的组织学分型进行鉴别诊断,并可以预测Ki-67增殖指数的表达水平。
文摘目的探讨多模态磁共振成像技术及其定量和定性参数预测胶质瘤Ki-67表达水平的价值。材料与方法选取330例胶质瘤患者,其中异柠檬酸脱氢酶(isocitrate dehydrogenase,IDH)野生型201例,IDH突变型129例。获得常规MRI特征、表观扩散系数(apparentdiffusion coefficient,ADC)、动态对比增强(dynamic contrast-enhanced,DCE)MRI定性及定量参数时间-强度曲线(time-intensity curve,TIC)、转运常数(volume transfer constant,K^(trans))、渗出速率常数(the rate constant,K_(ep))、血管外细胞外容积分数(fractional volume of the extravascular-extracellular,V_(e))、血浆分数(plasma fraction,V_(p))及磁共振波谱(magnetic resonance spectroscopy,MRS)代谢产物比值,对胶质瘤患者进行logistic回归,以确定与Ki-67表达水平相关因素。用受试者工作特征曲线下面积(area under the curve,AUC)评价预测模型的性能。结果在胶质瘤患者分析中,K^(trans)(OR=1.012,P<0.001)、ADC(OR=0.998,P<0.05)、强化程度(OR=3.317,P<0.05)是Ki-67表达水平的独立预测因素,AUC为0.893。结论K^(trans)、ADC和强化程度可能是预测胶质瘤Ki-67表达水平的有效参数。
文摘目的旨在评估动态对比增强磁共振成像(dynamic contrast-enhancement magnetic resonance imaging,DCE-MRI)结合扩散加权成像(diffusion weighted imaging,DWI)在预测前列腺癌(prostate cancer,PCa)Ki-67表达和Gleason评分中的诊断效能。材料与方法回顾性分析了2019年1月至2023年10月自贡市第四人民医院收治的66例PCa患者的临床及影像资料。结合T2WI、DWI序列和由DWI自动计算出的表观扩散系数(apparent diffusion coeffieient,ADC),在DCE-MRI图像上手动勾画肿瘤感兴趣区(region of interest,ROI),计算ROI药代动力学参数,包括容积转运常数(volume transfer contrast,K^(trans))、速率常数(rate contrast,K_(ep))、血管外细胞外容积分数(extravascular extracellular volume fraction,Ve),并测量ADC值。根据靶向穿刺病理诊断Gleason评分和Ki-67表达水平,分为Ki-67高表达组(Ki-67>10%)和低表达组(Ki-67≤10%),Gleason评分低级别(GG 1~2)和高级别(GG 3~5)组。组间差异比较使用两独立样本t检验或非参数检验,采用Spearman相关分析评价DCE-MRI参数和ADC值与Ki-67、Gleason评分的相关性,并建立logistic回归模型,通过受试者工作特征(receiver operating characteristic,ROC)曲线评估诊断效能。结果ADC值与Ki-67表达、Gleason评分均呈负相关(P<0.001),K^(trans)、K_(ep)、Ve与Ki-67表达均呈正相关(P<0.001),K^(trans)、K_(ep)与Gleason评分均呈正相关(P<0.001)。Ki-67高、低表达组K^(trans)、K_(ep)、Ve、ADC值比较差异均具有统计学意义(P<0.01),Gleason评分高、低级别组K^(trans)、K_(ep)、ADC值比较差异均具有统计学意义(P<0.01);Ki-67表达的ROC曲线分析显示,联合模型K^(trans)+K_(ep)+Ve+ADC诊断效能最好,曲线下面积(area under the curve,AUC)为0.940;Gleason评分分级的ROC曲线分析显示,联合模型K^(trans)+K_(ep)+ADC诊断效能最好,AUC为0.861。结论DCE-MRI的药代动力学参数和ADC值相结合,在预测PCa的Ki-67表达和Gleason评分中显示出高诊断效能。联合使用DCE-MRI定量参数与ADC值可提高PCa病理分级和生物侵袭性的预测准确性。
